AstraZeneca delivers third vaccine success in as many weeks

23 November 2020
astrazeneca_big

Safe and effective vaccines for the novel coronavirus seem to be like buses: after a long, anxious period of waiting, finally three come along at once.

On Monday, British drugmaker AstraZeneca (LSE: AZN) added positive high-level data for its candidate, AZD1222, to a growing list of encouraging clinical results - following first Pfizer (NYSE: PFE) and BioNTech (Nasdaq: BNTX), and then Moderna (Nasdaq: MRNA).

One dosing regimen showed vaccine efficacy of 90%, while another showed 62%, yielding an average result of 70%. Safety data were also highly encouraging.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology